Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the (a) diagnosis and (b) treatment of multiple sclerosis.

At the national level, there are a number of initiatives supporting service improvement and better care for patients with multiple sclerosis (MS), including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit.

NHS England has also established a Neurology Transformation Programme, a multi-year, clinically led programme, which has developed a new model of integrated care to support integrated care boards (ICBs) to deliver the right service, at the right time for all neurology patients, including those with MS. This focuses on providing access equitably across the country, care as close to home as possible, and early intervention to prevent illness and deterioration in patients with long-term neurological conditions. A toolkit is being developed to support ICBs to understand and implement this new model, which will include components on delivering acute neurology services, improving health equity in neurology, and improving community neurology services. The Neurology Transformation Programme has developed an Adult Neurology ICB dashboard, which includes specific data on MS disease-modifying therapies. Additionally, NHS England has also developed guidance for systems on improving access to disease-modifying treatments for MS closer to home, which includes successful delivery models and good practice case studies.

We have set up a United Kingdom-wide Neuro Forum, facilitating formal, biannual meetings across the Department, NHS England, the devolved administrations and health services, and the Neurological Alliances of all four nations. The new forum brings key stakeholders together, to share learnings across the system and discuss challenges, best practice examples, and potential solutions for improving the care of people with neurological conditions, including MS.

The National Institute for Health and Care Excellence (NICE) has produced guidance on the management of MS in adults, which includes a number of recommendations on recognising the signs and symptoms of MS and the initial assessment and diagnosis of MS. NICE has recommended a number of new medicines for use in the treatment of relapsing-remitting MS that are now routinely available for use in the treatment of National Health Service patients. In December 2024, NICE recommended Ublituximab for treating relapsing-remitting MS, and more recently in April 2025, NICE recommended Cladribine for treating active relapsing-remitting forms of MS.